RHHBY - This Biotech Stock Is Poised For 80% Upside With Breakthrough In Obesity Drug Market Says JPMorgan | Benzinga
The Structure Therapeutics (NASDAQ:GPCR) stock has been identified as a potential winner in the obesity drug market. JPMorgan has given the stock a significant upside potential.
What Happened: JPMorgan has initiated coverage of Structure Therapeutics, a biotech company, with an “Overweight” rating and a price target of $65, indicating an 80% potential upside from the current levels. The bank has identified Structure Therapeutics as a key player in the rapidly growing market for GLP-1 weight loss drugs, reported Business Insider.
Structure Therapeutics is developing a drug candidate called “1290,” which is an oral pill designed for the GLP-1 weight loss market. This drug is based on a small molecule formulation that could potentially hit the market one to two years ahead of competitors.
The drug is expected to offer significant weight ...